Friday 6 November 2026 Export LNTH’s income statement to Excel — free account

Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.

Revenue: +1.54%
EPS: −17.1%
Free cash flow: +7.71%
Total debt: +0.52%

Quarter to September 2026, against a year earlier

Revenue growth 5 yrs

100.76 0.38 −0.38%

Follow LNTH

Alert me

Market cap: $6.6B
P/E: 24.3×
Fwd P/E: 21.3×
Dividend yield: —
F-score: 5/9
Altman Z: 4.25
Beneish M: −2.23
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Lantheus Holdings, Inc. (LNTH) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by regions, and margins
United States	1,459	94.63%
Rest of world	83	5.37%
Gross margin		61.10%
Operating margin		20.16%
Pre-tax margin		20.35%

Revenue by product or service $m

Line	FY2024	FY2023	FY2022	FY2021	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013
Product revenue, net	1,525 99.40%	1,263 97.43%	887 94.86%	400 94.16%	—	—	—	—	—	—
License and royalty revenues	9 0.60%	33 2.57%	48 5.14%	25 5.84%	—	—	—	—	—	—
Other Nuclear	—	—	—	—	74 21.63%	—	—	—	—	—
Rebates And Allowances	—	—	—	—	(13) (3.74%)	—	—	—	—	—
Other Products	—	—	—	—	—	69 20.96%	71 23.53%	60 20.49%	76 25.10%	81 28.65%
Xenon	—	—	—	—	—	—	—	49 16.66%	37 12.12%	32 11.32%
Also reported: a second breakdown of the same revenue
PYLARIFY	1,058 68.96%	851 65.67%	527 56.40%	43 10.21%	—	—	—	—	—	—
DEFINITY	318 20.72%	280 21.58%	245 26.20%	233 54.74%	183 53.32%	157 47.46%	132 43.60%	112 38.12%	96 31.75%	78 27.53%
TechneLite	95 6.23%	87 6.74%	89 9.50%	91 21.47%	99 28.79%	105 31.58%	99 32.87%	73 24.73%	94 31.03%	92 32.50%
Strategic partnerships and other revenue	38 2.49%	52 4.00%	47 5.01%	25 5.95%	—	—	—	—	—	—
Other precision diagnostics	24 1.58%	23 1.77%	23 2.44%	27 6.34%	—	—	—	—	—	—
Other radiopharmaceutical oncology	0 0.03%	3 0.24%	4 0.44%	5 1.29%	—	—	—	—	—	—
Neuraceq	0 0.00%	0 0.00%	—	—	—	—	—	—	—	—
Total oncology	1,058	854	532	49	—	—	—	—	—	—
Total precision diagnostics	438	390	357	351	—	—	—	—	—	—
Revenue	1,534	1,296	935	425	343	331	302	293	302	284

Revenue by segment $m

Line	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013
Us	295 86.86%	304 87.52%	289 84.04%	290 87.51%	257 85.28%	236 80.36%	237 78.42%	235 82.69%
International	45 13.14%	43 12.48%	55 15.96%	41 12.49%	44 14.72%	58 19.64%	65 21.58%	70 24.69%
Eliminations	—	—	—	—	—	—	—	(21) (7.38%)
Worldwide	—	—	—	331	—	—	—	—
Revenue	339	347	343	331	302	293	302	284

Operating income by segment $m, and margin

	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013
International	‡	‡	‡	‡	‡	‡	‡	‡
Us	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013
United States	1,459 94.63%	1,485 96.79%	1,262 97.36%	289 84.04%	290 87.51%	257 85.28%	236 80.36%	237 78.42%	214 75.31%
Rest of world	83 5.37%	49 3.21%	34 2.64%	—	—	—	—	—	—
All Other	—	—	—	55 15.96%	41 12.49%	44 14.72%	29 9.98%	34 11.18%	35 12.17%
Canada	—	—	—	—	—	—	28 9.66%	31 10.40%	36 12.52%
Revenue	1,542	1,534	1,296	343	331	302	293	302	284

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.